MEG3基因在骨肉瘤中的研究进展

Research progress of MEG3 gene in osteosarcoma

骨肉瘤(osteosarcoma,OS)是最常见的一种骨组织原发性恶性肿瘤,其病变部位主要位于长骨干骺端,临床表现为持续性疼痛并伴有夜间加重。OS在年轻患者中发病率较高,根据美国国立卫生研究院统计,其发病率在10~19岁时达到峰值[1]。

Osteosarcoma(OS)is one of the most common primary bone malignancies,which is most common in children and young patients.Due to its high malignancy and poor treatment effect,its pathogenesis and treatment methods have become a hot spot in clinical research.Studies have shown that MEG3 gene(maternally expressed gene 3)can inhibit the occurrence of osteosarcoma by regulating p53 protein.It promotes the proliferation and invasion of osteosarcoma cells,regulates apoptosis,and promotes blood vessel regeneration by controlling PI3K/AKT signaling pathway,thus affecting the development of osteosarcoma.In addition,DNA methylation of MEG3 gene is also closely related to the diagnosis and treatment effect of osteosarcoma.This paper reviews the research progress of MEG3 gene in osteosarcoma,providing new ideas and basis for the exploration of diagnosis and treatment of osteosarcoma.